Levetiracetam Solution
Product Images NDC 70518-3803

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-3803). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
This is a description of a medication called LevETIRAcetam in oral solution form. Each cup contains 750mg of the medication in 7.5 mL. The package includes 10 cups of this solution. The medication is repackaged by RemedyRepack Inc. The prescription is only available with a prescription. The NDC number for the medication is 70518-3802-00. The expiration date and lot number are not mentioned in the provided text. The medication is manufactured by Aurohindo in Nagar, India. It is important to store the medication at a temperature between 20-25°C (88-77°F) and excursions are permitted between 15-30°C (59-86°F) as per the USP guidelines. It is important to keep this medication and all medications out of the reach of children. The provided text does not include specific usage instructions, so it is recommended to refer to the package insert for more information.*
FDA Label Image

Mm5 (Levetiracetam 1250mg 12.5ml 70518 3803 04)

FDA Label Image

Mm6 (Levetiracetam 1250mg 12.5ml 70518 3803 05)

FDA Label Image

Mm9 (Levetiracetam 1500mg 15ml 70518 3803 08)

Mm9 (Levetiracetam 1500mg   15ml 70518 3803 08)
This is a description of a medication called levETIRAcetam. It is an oral solution with a strength of 1500mg / 15mL. The package contains 10 cups, each with 15mL of the solution. The medication is manufactured by Aurohindo in Nagar, India. The NDC number is 70518-3802-08 and the source NDC is 65862-0250-47. The medication should be stored at 20-25°C (88-77°F), with excursions permitted between 15-30°C (59-86°F). The medication is repackaged by RemedyRepack Inc. in Indiana, PA. The lot number and expiration date are not available. It is important to keep this medication and all medications out of the reach of children. For further instructions, please refer to the package insert.*
FDA Label Image

Mm10 (Levetiracetam 1500mg 15ml 70518 3803 09)

FDA Label Image

Mm7 (Levetiracetam 2000mg 20ml 70518 3803 06)

Mm7 (Levetiracetam 2000mg   20ml 70518 3803 06)
This is a description of a medication called levETIRAcetam. It is an oral solution with a strength of 2000mg / 20 mL. The medication is packaged in cups, with each cup containing 20mL of the solution. The medication is repackaged by RemedyRepack Inc. and the original manufacturer is Aurohindo located in Nagar, India. The medication should be stored at a temperature between 20-25°C (88-77°F), with excursions permitted between 15-30°C (59-86°F). It is important to keep this medication out of the reach of children.*
FDA Label Image

Mm8 (Levetiracetam 2000mg 20ml 70518 3803 07)

Mm8 (Levetiracetam 2000mg   20ml 70518 3803 07)
This is a description of a medication labeled as "levETIRAcetam." It is an oral solution with a strength of 2000mg per 20 mL. The product is packaged in a 20 mL container and must be stored at a temperature range of 20-25°C (88-77°F) with excursions permitted up to 15-30°C (59-86°F). The medication is intended for use as directed, and caution must be taken to keep it out of the reach of children. The manufacturing company is Aurohindo, located in Nagar, India. The product has been repackaged by RemedyRepack Inc. in Indiana, PA.*
FDA Label Image

Mm3 (Levetiracetam 500mg 5ml 70518 3803 02)

Mm3 (Levetiracetam 500mg   5ml 70518 3803 02)
This is an evaluation of a medication labeled as "levETIRAcetam." It is an oral solution with a strength of 500mg/5mL. The package contains 10 cups, each with a volume of 5mL. The medication should be stored at temperatures between 20-25°C (88-77°F) with excursions permitted between 15-30°C (59-86°F) according to USP guidelines. The manufacturer is Aurohindo located in Nagar, India. The medication is repackaged by RemedyRepack Inc. in Indiana, PA. The NDC code for this medication is 70518-3802-02, and the source NDC is 65862-0250-47. The lot number and expiration date are not provided. It is important to keep this medication out of the reach of children.*
FDA Label Image

Mm4 (Levetiracetam 500mg 5ml 70518 3803 03)

Mm4 (Levetiracetam 500mg   5ml 70518 3803 03)
This text provides information about a medication labeled as "R A RX ONLY". The medication is an Oral Solution with a concentration of 500mg in 5 mL. The NDC (National Drug Code) for this medication is 70518-3802-02. The manufacturing company is Aurohindo located in Nagar, India. The expiration date and lot number are not available in the provided text. The source NDC for the medication is 65862-0250-47. The text also mentions to keep this medication, along with all others, out of the reach of children. The medication is packed by RemedyRepack Inc., located in Indiana, PA (Pennsylvania) with contact number 724.465.8762. The directions for use are indicated on the package insert. The recommended storage temperature is between 20-25°C (68-77°F), with excursions permitted between 15-30°C (59-86°F) according to USP (United States Pharmacopeia) guidelines.*
FDA Label Image

Mm2 (Levetiracetam 750mg 7.5ml 70518 3803 01)

Mm2 (Levetiracetam 750mg   7.5ml 70518 3803 01)
This is a description of a medication. The medication is called levETIRAcetam and it is in the form of an oral solution with a strength of 750mg / 7.5 mL. The package contains 7.5 mL of the medication. The medication is intended for use as directed, which can be found in the package insert. It should be stored between 20-25°C (88-77°F), with excursions permitted between 15-30°C (59-86°F). The medication was repackaged by RemedyRepack Inc. in Indiana, PA. The manufacturer of the medication is Aurohindo, located in Nagar, India. The product is for prescription use only and should be kept out of the reach of children. The expiration date and lot number are not available in the provided text.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
Figure 1 shows the responder rate in Study 1, indicating a reduction of 250% from the baseline. The text also mentions Lovcasetam and Lovtiactan, with their respective doses of 100 mg and 3000 mg. The results are statistically significant compared to the placebo.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
The text provides data on the "Responder Rate" for patients aged between 1 month to less than 4 years in Study 5. The percentages indicate the reduction from baseline for different groups. Unfortunately, the exact details of the reduction are not available due to incomplete . However, it is mentioned that there is a statistically significant difference between the placebo group (N=51) and the levetiracetam group (N=58).*
FDA Label Image

Table 15: Median Percent Reduction From Baseline In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Table 15: Median Percent Reduction From Baseline In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
This text provides information about a study (Study 7) evaluating the responder rate (250% reduction from baseline) in the frequency of generalized tonic-clonic (PGTC) seizures per week. The figure shows the percentage of patients who experienced a reduction in PGTC seizure frequency. The percentage of responders is shown on the y-axis, ranging from 0% to 100%, while the x-axis represents the treatment groups (Placebo and Levetiracetam). The text indicates that the results for Levetiracetam were statistically significant compared to the placebo group.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.